Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of E7386 in combination with other anticancer drugs in solid tumors
CTR20250484Phase 2Active
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of e7386, lenvatinib in endometrial cancer (EC), hepatocellular carcinoma (HCC), colorectal cancer (CRC), Nonhematologic neoplasms, sponsored by Eisai Co., Ltd.. Started Apr 2025; status: active.
02
Drugs
e7386lenvatinib
03
Conditions
endometrial cancer (EC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20250484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250484.